Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma

Jennifer Nguyen, Richard Bernert, Kevin In, Paul Kang, Noemi Sebastiao, Chengcheng Hu, Karen Taraszka Hastings

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

T-cell-mediated immunity has the ability to produce durable antimelanoma responses, resulting in improved survival of patients with advanced melanoma. Antigen presentation is a key determinant of T-cell responses. Gamma-interferoninducible lysosomal thiol reductase (GILT) is critical for MHC class II-restricted presentation of multiple melanoma antigens to CD4+ T cells. However, GILT expression in melanoma has not been defined. We evaluated GILT and MHC class II expression in human primary and metastatic melanomas and nevi using immunohistochemical analysis. GILT staining in melanocytes was observed in 70% of primary and 58% of metastatic melanomas versus 0% of nevi. When present, the GILT staining intensity in melanocytes was typically faint. Both GILT and MHC class II expression were increased in melanocytes of primary and metastatic melanomas compared with nevi. GILT staining in antigen-presenting cells (APCs) was detected in 100% of primary and metastatic melanomas versus 31% of nevi, and it was typically intense. GILT expression was increased in APCs of primary and metastatic melanomas compared with nevi, whereas MHC class II had equivalent high expression in APCs of all melanocytic lesions. GILT staining in keratinocytes was detected in 67% of primary melanomas versus 14% of nevi and 6% of metastatic melanomas. GILT, but not MHC class II, expression was increased in keratinocytes of primary melanomas compared with nevi and metastases. GILT expression is anticipated to result in improved presentation of melanoma antigens and more effective antimelanoma T-cell responses. GILT expression may be a biomarker of immune recognition of melanoma.

Original languageEnglish (US)
Pages (from-to)125-137
Number of pages13
JournalMelanoma Research
Volume26
Issue number2
DOIs
StatePublished - Mar 23 2016

Fingerprint

Sulfhydryl Compounds
Interferon-gamma
Melanoma
Oxidoreductases
Nevus
Melanocytes
Antigen-Presenting Cells
Staining and Labeling
Melanoma-Specific Antigens
T-Lymphocytes
Keratinocytes
Nevi and Melanomas
Antigen Presentation
Cellular Immunity
Biomarkers
Neoplasm Metastasis
Survival

Keywords

  • Antigen presentation
  • HLA-D antigens
  • Human
  • IFI30 protein
  • Melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Dermatology

Cite this

Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma. / Nguyen, Jennifer; Bernert, Richard; In, Kevin; Kang, Paul; Sebastiao, Noemi; Hu, Chengcheng; Hastings, Karen Taraszka.

In: Melanoma Research, Vol. 26, No. 2, 23.03.2016, p. 125-137.

Research output: Contribution to journalArticle

Nguyen, Jennifer ; Bernert, Richard ; In, Kevin ; Kang, Paul ; Sebastiao, Noemi ; Hu, Chengcheng ; Hastings, Karen Taraszka. / Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma. In: Melanoma Research. 2016 ; Vol. 26, No. 2. pp. 125-137.
@article{1ef9c1c74ccb48ae9095aa232dcb1522,
title = "Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma",
abstract = "T-cell-mediated immunity has the ability to produce durable antimelanoma responses, resulting in improved survival of patients with advanced melanoma. Antigen presentation is a key determinant of T-cell responses. Gamma-interferoninducible lysosomal thiol reductase (GILT) is critical for MHC class II-restricted presentation of multiple melanoma antigens to CD4+ T cells. However, GILT expression in melanoma has not been defined. We evaluated GILT and MHC class II expression in human primary and metastatic melanomas and nevi using immunohistochemical analysis. GILT staining in melanocytes was observed in 70{\%} of primary and 58{\%} of metastatic melanomas versus 0{\%} of nevi. When present, the GILT staining intensity in melanocytes was typically faint. Both GILT and MHC class II expression were increased in melanocytes of primary and metastatic melanomas compared with nevi. GILT staining in antigen-presenting cells (APCs) was detected in 100{\%} of primary and metastatic melanomas versus 31{\%} of nevi, and it was typically intense. GILT expression was increased in APCs of primary and metastatic melanomas compared with nevi, whereas MHC class II had equivalent high expression in APCs of all melanocytic lesions. GILT staining in keratinocytes was detected in 67{\%} of primary melanomas versus 14{\%} of nevi and 6{\%} of metastatic melanomas. GILT, but not MHC class II, expression was increased in keratinocytes of primary melanomas compared with nevi and metastases. GILT expression is anticipated to result in improved presentation of melanoma antigens and more effective antimelanoma T-cell responses. GILT expression may be a biomarker of immune recognition of melanoma.",
keywords = "Antigen presentation, HLA-D antigens, Human, IFI30 protein, Melanoma",
author = "Jennifer Nguyen and Richard Bernert and Kevin In and Paul Kang and Noemi Sebastiao and Chengcheng Hu and Hastings, {Karen Taraszka}",
year = "2016",
month = "3",
day = "23",
doi = "10.1097/CMR.0000000000000230",
language = "English (US)",
volume = "26",
pages = "125--137",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma

AU - Nguyen, Jennifer

AU - Bernert, Richard

AU - In, Kevin

AU - Kang, Paul

AU - Sebastiao, Noemi

AU - Hu, Chengcheng

AU - Hastings, Karen Taraszka

PY - 2016/3/23

Y1 - 2016/3/23

N2 - T-cell-mediated immunity has the ability to produce durable antimelanoma responses, resulting in improved survival of patients with advanced melanoma. Antigen presentation is a key determinant of T-cell responses. Gamma-interferoninducible lysosomal thiol reductase (GILT) is critical for MHC class II-restricted presentation of multiple melanoma antigens to CD4+ T cells. However, GILT expression in melanoma has not been defined. We evaluated GILT and MHC class II expression in human primary and metastatic melanomas and nevi using immunohistochemical analysis. GILT staining in melanocytes was observed in 70% of primary and 58% of metastatic melanomas versus 0% of nevi. When present, the GILT staining intensity in melanocytes was typically faint. Both GILT and MHC class II expression were increased in melanocytes of primary and metastatic melanomas compared with nevi. GILT staining in antigen-presenting cells (APCs) was detected in 100% of primary and metastatic melanomas versus 31% of nevi, and it was typically intense. GILT expression was increased in APCs of primary and metastatic melanomas compared with nevi, whereas MHC class II had equivalent high expression in APCs of all melanocytic lesions. GILT staining in keratinocytes was detected in 67% of primary melanomas versus 14% of nevi and 6% of metastatic melanomas. GILT, but not MHC class II, expression was increased in keratinocytes of primary melanomas compared with nevi and metastases. GILT expression is anticipated to result in improved presentation of melanoma antigens and more effective antimelanoma T-cell responses. GILT expression may be a biomarker of immune recognition of melanoma.

AB - T-cell-mediated immunity has the ability to produce durable antimelanoma responses, resulting in improved survival of patients with advanced melanoma. Antigen presentation is a key determinant of T-cell responses. Gamma-interferoninducible lysosomal thiol reductase (GILT) is critical for MHC class II-restricted presentation of multiple melanoma antigens to CD4+ T cells. However, GILT expression in melanoma has not been defined. We evaluated GILT and MHC class II expression in human primary and metastatic melanomas and nevi using immunohistochemical analysis. GILT staining in melanocytes was observed in 70% of primary and 58% of metastatic melanomas versus 0% of nevi. When present, the GILT staining intensity in melanocytes was typically faint. Both GILT and MHC class II expression were increased in melanocytes of primary and metastatic melanomas compared with nevi. GILT staining in antigen-presenting cells (APCs) was detected in 100% of primary and metastatic melanomas versus 31% of nevi, and it was typically intense. GILT expression was increased in APCs of primary and metastatic melanomas compared with nevi, whereas MHC class II had equivalent high expression in APCs of all melanocytic lesions. GILT staining in keratinocytes was detected in 67% of primary melanomas versus 14% of nevi and 6% of metastatic melanomas. GILT, but not MHC class II, expression was increased in keratinocytes of primary melanomas compared with nevi and metastases. GILT expression is anticipated to result in improved presentation of melanoma antigens and more effective antimelanoma T-cell responses. GILT expression may be a biomarker of immune recognition of melanoma.

KW - Antigen presentation

KW - HLA-D antigens

KW - Human

KW - IFI30 protein

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=84961785421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961785421&partnerID=8YFLogxK

U2 - 10.1097/CMR.0000000000000230

DO - 10.1097/CMR.0000000000000230

M3 - Article

C2 - 26930048

AN - SCOPUS:84961785421

VL - 26

SP - 125

EP - 137

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 2

ER -